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ABSTRACT
Background. 5-Fluorouracil (5-FU) is administered based
on standard body surface area (BSA) dosing. BSA admin-
istration results in highly variable exposure, measured as
the area under the concentration-time curve (AUC). An
immunoassay (OnDose; Myriad Genetic Laboratories,
Inc., Salt Lake City, UT) that measures plasma 5-FU con-
centration and reports an AUC in mg  h/L has been devel-
oped to optimize therapy using pharmacokinetic (PK)
dosing. The results of an analysis to model the 5-FU AUC-
dose relationship are presented.
Methods. A set of 589 sequential patients from a clinical
database receiving 5-FU, leucovorin, and oxaliplatin (the
FOLFOX6 regimen) for colorectal cancer (CRC) treat-
ment was analyzed. A subset including only patients who
had at least two consecutive cycles tested, received 1,600–
3,600 mg/m2 of continuous infusion 5-FU during the initial
test cycle, and had a blood sample collected after >18
hours, was used to conduct regression modeling of the
change in AUC versus change in dose.
Results. A simple regression model with R2  0.51 devel-
oped over n  307 cycle-pair observations characterizes
the AUC-Dose relationship as: change in AUC  0.02063 *
dose change. The model suggests that dose changes in the
range of 145–727 mg/m2 would be sufficient to adjust the
AUC to a potential therapeutic threshold of >20 mg  h/L
for most patients.
Conclusions. 5-FU is an ideal candidate for PK dose op-
timization. Because individual factors other than dose
change may also affect the change in AUC, longitudinal PK
monitoring in all cycles and dose adjustment to ensure
AUC in the desired range of 20–30 mg  h/L are recom-
mended. The Oncologist 2012;17:296–302
INTRODUCTION
In the treatment of cancer patients with cytotoxic drugs, a
prime consideration is improving the therapy outcome by in-
creasing efficacy while maintaining an acceptable toxicity pro-
file. Thus, fine tuning of chemotherapy needs to consider the
generally wide interindividual pharmacokinetic (PK) variabil-
ity of such drugs and the finding that general toxicity and effi-
cacy are more related to systemic exposure than to dose and
dose intensity [1–3]. 5-fluorouracil (5-FU), which has been
used in the treatment of a variety of solid tumors, is a prime
example of this concept [4, 5].
5-FU has been the cornerstone of colorectal cancer (CRC)
therapy since the 1960s, with regimens having undergone a se-
ries of modifications in order to enhance the benefits to pa-
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tients, ranging from enhanced monotherapy to multiagent
polychemotherapy including irinotecan and oxaliplatin, and
more recently, the addition of the targeted agents bevacizumab
and anti–epidermal growth factor receptor antibodies. There
has been a progressive improvement throughout the years in
survival outcomes for these patients, but 5-FU has remained
the cornerstone and the most important component of these
regimens.
Like other chemotherapeutic drugs, 5-FU is generally
characterized by a narrow therapeutic index and a large inter-
individual PK variability that has a direct effect on both toxic-
ity and efficacy [4, 5]. Regardless of the regimen and schedule
in which 5-FU is used, the method of dosing 5-FU in standard
practice has not changed for decades and is based on the tradi-
tional use of body surface area (BSA). Although BSA dosing is
convenient and easy to use, a number of studies have shown it
to underestimate or overestimate exposure and clearance in the
majority of patients treated, because there is no correlation
among plasma clearance, exposure, and BSA. Studies have
shown a very high level of variability in the exposure and
clearance of 5-FU, suggesting the potential for underdosing of
a significant proportion of patients and some greater risk for
toxicity because of overdosing [6]. Sequential measurements
of 5-FU area under the concentration-time curve (AUC) along
cycles in a commercial database have also shown a wide dis-
tribution in exposure, with subsequent nonuniform dose
changes resulting in a narrowing of the AUC distribution [7].
This 5-FU PK variability is affected by various factors, such as
genotype, age, gender, disease state, drug–drug interactions,
and organ function, as well as other not well-quantified factors.
Of particular concern is the potential for underdosing of obese
patients, which can adversely influence the treatment outcome
in this rapidly growing part of the U.S. population [8–9]. Ad-
ditionally, the effect of BSA dose calculation may lead to un-
derdosing as a result of the practice of “dose capping” because
of fear of overdosing [10].
One of the most significant a priori contributors to this PK
variability of 5-FU has been the heterogeneity of the activity of
the enzyme responsible for the metabolism of 5-FU, dihydro-
pyrimidine dehydrogenase [11]. However, this accounts for a
small minority of patients with a rare pharmacogenetic disor-
der, and the majority of the 5-FU PK variability occurs a pos-
teriori after the drug has been administered, as shown in a study
by Adjei et al. [12]. That study systematically confirmed the
inherent inter- and intrapatient PK variability of 5-FU in serial
measurements in patients receiving continuous i.v. 5-FU. Con-
trary to expectations, that study also showed that 5-FU concen-
trations do not seem to reach steady state until about 18 hours
into the infusion.
Measurements of systemic exposure of 5-FU, such as the
AUC, have been shown to correlate with toxicity, tumor re-
sponse, and survival outcomes [13–17]. Most of these studies
suggest that better responses occurred in patients with a mean
5-FU AUC in the range of 20–30 AUC units (mg  h/L) [13,
18]. Patients with 5-FU AUC below this level are receiving
suboptimal therapeutic doses and those with 5-FU AUC above
this range are at a greater risk for toxicity [19–21]. A higher
response rate (39% versus 19%) and longer median overall
survival (OS) time (22 months versus 16 months) were dem-
onstrated in a phase III randomized trial comparing PK-guided
dosing with a target AUC of 20–25 mg  h/L with conventional
BSA dosing of infusional 5-FU [22]. Thus, the administration
of 5-FU is an ideal candidate for personalizing dosing using
individual PK parameters as a guide for optimizing therapy.
AUC has been demonstrated to be the pharmacokinetic param-
eter that is most closely associated with efficacy and toxicity.
Attempts at finding the right balance of maximizing exposure
while limiting toxicity have been published, with favorable
data, and indicate that there is a potential for optimizing 5-FU
administration.
This retrospective analysis of PK data from a commercial
laboratory setting is the first attempt to define a dose adjust-
ment algorithm for 5-FU for the 5-FU, leucovorin, and oxalip-
latin (FOLFOX6) regimen based on experience with infusions
in a U.S. CRC patient population.
METHODS AND PATIENTS
5-FU AUC Measurement
Plasma samples collected from patients were shipped to Myr-
iad Genetic Laboratories, Inc. (Salt Lake City, Utah) for anal-
ysis. In the laboratory, the samples are filtered by spin column
with a 100-kDa cutoff and the filtrate is used for the analysis.
5-FU measurement is performed using the OnDose (Myriad
Genetic Laboratories, Inc., Salt Lake City, UT) assay, a com-
petitive homogeneous two-reagent nanoparticle agglutination
immunoassay. The first reagent contains 5-FU conjugate with
the second reagent consisting of 5-FU– directed antibody-
conjugated nanoparticles. The amount of free 5-FU in the
plasma inhibits aggregation of the two assay reagents. The
amount of light absorbance at certain wavelengths from
the nanoparticle agglutination depends on the amount of drug
in plasma. This absorbance is compared with a standardized
calibration curve for quantization. This method was adapted,
developed, and crossvalidated at Myriad Genetic Laboratories,
Inc., from a technique that previously had been validated
against liquid chromatography–tandem mass spectrometry.
The quantitative target range for 5-FU exposure, as expressed
by the AUC, is calculated from the measured concentration of
5-FU and the infusion duration using standard methods.
Patients
Anonymized patient data were gathered from the commercial
database (Myriad Genetic Laboratories, Inc.) from informa-
tion entered on the test request forms for the 5-FU immunoas-
say (OnDose). The following information was collected for
this analysis: gender, age, pathological diagnosis of CRC, date
of infusion, type of treatment (metastatic or adjuvant), type of
infusional therapy (FOLFOX; 5-FU, leucovorin, and irinote-
can; bevacizumab, other), total dose for infusion, duration of
infusion, and time of sample draw from start of infusion.
Description of Analysis Datasets
The OnDose test database has 3,000 observations (AUC mea-
surements) from 1,300 patients in the U.S. clinical setting.
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These patients have been referred by 500 physicians from var-
ious academic institutions, as well as community oncology prac-
tices, from 48 states. Because the data were collected from limited
information submitted on test request forms in a commercial set-
ting, there are data issues, such as missing values, as well as in-
formation gaps, such as a lack of information regarding the exact
reasons for dose change decisions.
The above database is very heterogeneous, containing ob-
servations from different indications, a variety of 5-FU–con-
taining regimens, and different infusion modalities. A fairly
homogeneous analysis dataset is needed to effectively analyze
the effects and relationships of interest. Therefore, the data-
base was queried to generate a preliminary analysis dataset of
1,221 observations from 589 patients receiving the FOLFOX6
regimen with continuous infusion 5-FU, with or without bev-
acizumab, for the adjuvant or metastatic treatment of CRC.
The initial aim was to evaluate the effects of sample col-
lection time on AUC measurements, in order to identify the op-
timal blood draw time for PK analysis. For most (96%) of the
observations in the dataset, the collection times are distributed
around three sample collection time modes: the beginning of
infusion (@2 hours), the middle of infusion (@22 hours), and
toward the end of infusion (@44 hours). As such, a restricted
analysis dataset of 1,172 observations from 572 patients was
derived from the preliminary analysis dataset of 1,221 obser-
vations by removing the few observations with collection
times in between these three modes. Extreme AUC outlier val-
ues (50 mg  h/L) were removed, because these might be re-
lated to sampling directly from the i.v. port or in proximity to it.
A critical requirement for developing any dosing algorithm
is to model the change in AUC versus the change in dose rela-
tionship. A longitudinal dataset with AUC measurements from
at least two consecutive cycles for each patient is needed for
such modeling. In the above preliminary analysis dataset of
1,221 observations, many patients had only a single AUC mea-
surement, whereas some others had more than one measure-
ment but not at consecutive infusion cycles.
Therefore, from the preliminary analysis dataset, a smaller
longitudinal modeling dataset was identified with the follow-
ing characteristics: (a) the patient had AUC measurements for
at least two consecutive infusion cycles with a dose change, (b)
the 5-FU dose received during the initial test cycle was 1,600–
3,600 mg/m2, (c) the blood sample collection times were 18
hours from the start of the 5-FU infusion for each cycle (based
on the findings from the collection time analyses), and (d) out-
liers such as AUC values 5 mg  h/L and 50 mg  h/L were
excluded.
A “cycle-pair observation” consists of measurements from
two consecutive infusion cycles for the same patient. So, a pa-
tient with AUC measurements at only two consecutive infu-
sion cycles would provide one cycle-pair observation for these
analyses, whereas a patient with AUC measurements at four
consecutive infusion cycles would provide three cycle-pair ob-
servations. In addition to meeting the above criteria, for each
cycle-pair observation to be included in the modeling dataset,
the patient needed to have a dose change between the two con-
secutive infusion cycles. The resulting modeling dataset con-
sists of 307 cycle-pair observations from 187 patients.
The difference in AUC between the two measurements con-
stituting a cycle-pair observation provides the “change in AUC”
in mg  h/L, whereas the corresponding difference in 5-FU dose
amount provides the “change in dose” in mg/m2. A simple regres-
sion analysis was then used to model the change in AUC (mg 
h/L) versus the change in dose (mg/m2) relationship.
RESULTS
Effect of Sample Collection Time on
AUC Measurement
The effects of sample collection time on AUC measure-
ments were evaluated in an analysis dataset of 1,172 single
observations. The mean AUC measurements were com-
pared among three collection time modes using a simple
analysis of variance model with AUC measurement as the
dependent variable and collection time mode as the factor
(Table 1). The mean 5-FU AUC level was significantly
lower when the blood sample was drawn in the early hours
of the infusion. This low mean value is likely caused by a
variety of factors, including varying rates of 5-FU metabo-
lism before steady-state conditions are reached and sam-
pling before the pump was fully primed with drug.
The statistically significant lower mean AUC value at
the 2-hour collection time mode indicates the existence of
large variability in 5-FU PK measurements during the early
part of the infusion cycle. Consequently, the analysis data-
set used for modeling the AUC versus dose relationship was
restricted to observations with sample collection times 18
hours after the start of the infusion, when there is less vari-
ability (Fig. 1).
Modeling the 5-FU AUC Versus 5-FU
Dose Relationship
The modeling of change in AUC versus change in 5-FU dose
relationship was conducted on a longitudinal modeling dataset
consisting of 307 cycle-pair observations from 187 patients.
Patient Characteristics
One hundred eighty-seven patients (104 male and 79 female)
receiving FOLFOX6 with or without bevacizumab were in-
cluded in the analysis (Table 2). The mean age was 58.2 years.
Table 1. Area under the concentration–time curve (AUC)

















@2 hours 101 16.8 6.80 NA .0003
@22 hours 396 20.2 7.36 .0003 NA
@44 hours 675 20.6 9.33 .0001 .5178
Abbreviation: NA, not applicable.
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Patient characteristics are summarized in Table 2. FOLFOX6
without bevacizumab was the therapy for 120 patients
(64.2%), and bevacizumab was added to the regimen for 67 pa-
tients (35.8%). One hundred eighteen patients (63.8%) had
metastatic disease, and 67 patients (36.2%) were treated with
an adjuvant intent. Some patients had missing values for one or
more of these variables.
Cycle-Pair Characteristics
Of the 307 cycle-pairs identified in the test cohort (Table 3),
109 patients (58.3%) had one cycle-pair, 46 patients (24.6%)
had two cycle-pairs, 22 patients (11.8%) had three cycle-pairs,
and 10 patients (5.3%) had four cycle-pairs. The baseline mean
dose was 2,263.4 mg/m2 (standard deviation [SD], 457.42 mg/
m2), and the baseline mean AUC was 20.2 mg  h/L (SD, 8.5
mg  h/L). The mean absolute dose change was 268.0 mg/m2
(absolute SD, 192.56 mg/m2) and the mean absolute change in
AUC was 6.9 mg  h/L (absolute SD, 6.53 mg  h/L).
Paired observations (n  307) were selected as described
above to examine the change in AUC versus change in dose
relationship. A regression model with R2  0.51 characterized
the AUC–dose relationship as: change in AUC (mg  h/L) 
0.02063 * dose change (mg/m2) (Fig. 2).
5-FU Dose Adjustment Based on Prior
AUC Reading
Using the AUC–dose relationship calculated above, a dose ad-
justment table was generated to provide a practical application
of the AUC measurement in modifying the subsequent dose in
order to bring exposure to the desired level (Table 4).
A Proposed Dose Adjustment Algorithm
Using the previous cycle 5-FU AUC value, it is suggested
that one can use Table 4 in order to calculate the increase or
decrease in the next 5-FU dose to achieve the desired 5-FU
AUC at the next cycle. However, for feasibility and adapt-
ability in a real clinical setting, a dose adjustment algorithm
is proposed for use in a clinically relevant dose range (Table
5). Based on commercial testing experience (3,000 tests),
it has become obvious that the proposed target range of
20 –24 mg  h/L in the literature is too narrow (a range of
Figure 1. Distribution of area under the concentration–time curve (AUC) by collection time mode.
Table 2. Patient summary statistics
Characteristic

















Abbreviation: FOLFOX6, 5-fluorouracil, leucovorin, and
oxaliplatin.
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only 4 mg  h/L units) to be useful in the presence of the vari-
ability in 5-FU PK readings. This algorithm suggests using
a 20 –30 mg  h/L target range. The lower limit of 20 mg  h/L
was considered valid based on published efficacy data [13,
18, 22]. However, the upper limit of 24 mg  h/L was gen-
erated using more toxic regimens of 5-FU administration
and may not be considered relevant for the less toxic newer
regimens. The upper limit of 30 mg  h/L is supported by
published data and is thus recommended as an upper limit of
target exposure [15, 20, 21, 23]. Consequently, the width of
the proposed target range is 10 mg  h/L, a range wide
enough to realistically accommodate the intrapatient 5-FU
PK variability, thus reducing the need for frequent and un-
necessary dose adjustments.
DISCUSSION
This analysis models a relationship that provides an algorithm
that allows dose changes to be dialed up or down, based on PK
parameters, to be within an optimal therapeutic range. The data
indicate that dose changes in the range of 291–727 mg/m2
would be sufficient to adjust the AUC to a potential therapeutic
threshold of 20 mg  h/L for most patients receiving FOL-
FOX6 with or without bevacizumab. Patients given doses that
result in AUC values under this threshold have a higher risk for
underdosing, with lesser efficacy. The analysis also provides
an upper threshold for potential greater toxicity. Assuming a
2,400 mg/m2 baseline dose, a maximum 727 mg/m2 dose in-
crease would correspond to a 30% increase and would be
needed only by patients who have an initial AUC measurement
10 mg  h/L. Previously published analyses using the same
commercial database show that only 10.4% of the patient pop-
ulation had such low initial AUC measurements at that dose
level [7].
The data for this study come from a commercial testing da-
tabase, rather than a controlled clinical trial. However, this is
the largest dataset of this type from a real-world clinical setting
in the U.S. This provides a certain degree of robustness to the
analysis results. A large efficacy trial to test the utility of this
dose adjustment algorithm is currently ongoing.
Dose adjustment algorithms based on 5-FU AUC have
been reported for some 5-FU– containing regimens, such as
weekly 8-hour infusion regimens with concomitant leuco-
vorin [20], long-term 5-FU with or without cisplatin [17],
and a bimonthly regimen of i.v. 5-FU with a bolus infusion
and a continuous infusion over the next 22 hours on two
consecutive days [19]. Effective individualized dose man-
agement of 5-FU in the treatment of CRC patients was dem-
onstrated in phase II and phase III trials. In a study of 152
CRC patients treated weekly with 1,300 mg/m2 5-FU (8-
hour infusion) and with 400 mg/m2 leucovorin, the weekly
dose was adapted based on a dose adjustment chart to reach
a predefined plasma concentration range of 2–3 mg/L
(AUC8, 16 –24 mg  h/L). This dose adjustment strategy was
associated with both superior efficacy and better tolerability
than with conventional BSA dosing [14].
This individualized dose optimization method was com-
pared with conventional BSA 5-FU infusion in a phase III ran-
domized trial of 208 CRC patients with a target AUC of 20–25
mg  h/L [22]. In that study, 70% of patients required adjust-
ment of their doses in order to achieve the optimal therapeutic
dose. Of these, 58% of patients required an increase in dose,
with 10%–20% requiring a dose reduction in order to have an
AUC within the optimal range. That trial demonstrated a
higher rate of complete and partial responses (39% versus
19%; p  .0004). The median OS times were 16 months for
patients in the BSA arm and 22 months for patients in the PK
arm (p  .08). Toxicity was seen in more patients receiving
BSA dosing than PK dosing (p  .003). Successful dose ad-
justment was achieved in 94% of the patients. Only 8% of pa-
tients receiving BSA dosing were found to have an AUC
within the optimal range.
The above studies clearly demonstrate that CRC therapy
with 5-FU–containing regimens is suited to therapeutic drug
monitoring and a posteriori dose adjustment based on individ-
ualized determination of PK parameters. However, the data in
these trials were generated using 5-FU monotherapy and dose
ranges that have currently been improved to include other
agents and use a more prolonged administration of 5-FU. One
of the most recent iterations of combination chemotherapy for
CRC is FOLFOX6 containing oxalipatin and leucovorin with
Table 3. Cycle-pair summary statistics
Cycle-pair characteristic
n (%) of cycle-pairs
(n  307)

























Abbreviation: AUC, area under the concentration–time
curve.
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or without bevacizumab. In that regimen 5-FU is administered
as a bolus of 400 mg/m2 and a continuous infusion of 2,400
mg/m2 over 46 hours. This prolonged administration of 5-FU
is associated with less 5-FU–related toxicity. The analysis pre-
sented in this paper and the suggested dose adjustment algo-
rithm take into account this greater tolerability of 5-FU with
this regimen, and in combination with data from the literature
suggest an optimal AUC range of 20–30 mg  h/L [22, 23]. The
analyses of the dose–exposure relationship reveal that it is pos-
sible to optimize the dose of 5-FU based on previous PK de-
termination and provide a practical guideline and a tool to
reach optimal target exposure levels by making modest adjust-
ments so that subsequent doses are within the desired range.
PROFUSE (PROspective 5-FluoroUracil OnDoSe Evalua-
tion), a large controlled clinical trial to test the utility of this
dose adjustment algorithm versus standard BSA dosing, is cur-
rently ongoing in the U.S. (ClinicalTrials.gov identifier,
NCT01468623) [24]. It is expected that positive efficacy re-
sults from this trial would lead to greater adoption of PK-
guided 5-FU dosing in the U.S.
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Table 4. Dose adjustment table








Abbreviation: AUC, area under the concentration–time
curve.
Table 5. Proposed dose adjustment algorithm














Abbreviation: AUC, area under the concentration–time
curve.
Figure 2. Change in 5-fluorouracil dose versus change in 5-fluorouracil area under the concentration–time curve (AUC) relationship.
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